VALNValneva SE
Price
-47%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early Research & Development (“R&D”) to approvals, and currently market three proprietary travel vaccines.
In the company’s own words · 20-F filed Mar 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Valneva SE (VALN) reported revenue of €48M in Q4 2025 (quarter ended Dec 31, 2025), down 9.9% from the same quarter a year earlier. That came with a gross margin of 24% and net loss of €50M. For the full year FY2025, revenue was €175M (+3.0% year on year) and net income −€115M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.